Holen Sie sich die Stockscreener-App
40.54
0.27%
0.1275
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Market Review: Is RBNE stock risky to hold now2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn
DLD Asset Management LP Acquires New Position in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Globe and Mail
Weekly Earnings: What is the implied volatility of Spyre Therapeutics IncMarket Activity Recap & Community Driven Trade Alerts - baoquankhu1.vn
Patterns Watch: Can Spyre Therapeutics Inc grow without external fundingMarket Trend Review & Technical Confirmation Trade Alerts - baoquankhu1.vn
Trading Recap: Can Spyre Therapeutics Inc deliver consistent EPS growthVolume Spike & Weekly Top Performers Watchlists - baoquankhu1.vn
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - AOL.com
Assessing Spyre Therapeutics (SYRE) Valuation After A Year Of Strong Shareholder Returns - Yahoo Finance
Insider Selling: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE) - GuruFocus
Scott Burrows Sells 2,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $632,850.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
Investment Review: Is Spyre Therapeutics Inc a top pick in the sectorPortfolio Return Report & Verified Entry Point Signals - baoquankhu1.vn
Spyre Therapeutics CEO Sells 15,000 Shares - TradingView
Support Test: Can Spyre Therapeutics Inc lead its sector in growthPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Aug Analyst Calls: Can Spyre Therapeutics Inc lead its sector in growth - baoquankhu1.vn
Insider Selling: Cameron Turtle Sells 15,000 Shares of Spyre The - GuruFocus
Morgan Stanley broker lists 60,000-share SYRE resale (SYRE) - Stock Titan
SYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[EFFECT] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
SYRE PE Ratio & Valuation, Is SYRE Overvalued - Intellectia AI
Spyre Therapeutics, Inc. (SYRE): Investor Outlook Amid A 35% Potential Upside - DirectorsTalk Interviews
[POS AM] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. targets breakthrough in inflammatory bowel disease with combination therapies - Traders Union
Spyre reports enhanced efficacy of anti-TL1A and anti-IL-23 combination - BioWorld MedTech
Assessing Spyre Therapeutics (SYRE) Valuation After A Powerful Multi‑Period Share Price Run - simplywall.st
Insider Sell: Can Spyre Therapeutics Inc maintain sales growthTrade Risk Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Spyre Therapeutics to Participate in Upcoming March Investor Conferences - Bitget
Bull Bear: Is Spyre Therapeutics Inc a top pick in the sector2025 Pullback Review & Weekly Top Performers Watchlists - baoquankhu1.vn
SYRESpyre Therapeutics Latest Stock News & Market Updates - Stock Titan
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Deutsche Bank Adjusts Spyre Therapeutics PT to $55 From $45, Maintains Buy Rating - marketscreener.com
Spyre Therapeutics stock dips premarket after Friday surge as $500 million shelf hangs over shares - TechStock²
Wells Fargo & Company Forecasts Strong Price Appreciation for Spyre Therapeutics (NASDAQ:SYRE) Stock - Defense World
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Spyre Therapeutics (SYRE) and Tandem Diabetes Care (TNDM) - The Globe and Mail
Gains Report: Can Spyre Therapeutics Inc. (3920) stock surprise markets with earningsMarket Sentiment Summary & Free Fast Entry Momentum Trade Alerts - mfd.ru
Analysts Offer Insights on Healthcare Companies: Organigram Global (OGI) and Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre Therapeutics (NASDAQ:SYRE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Spyre Therapeutics stock hits 52-week high at 42.93 USD - Investing.com India
Spyre Therapeutics (SYRE) Buy Rating Reiterated by BTIG | SYRE S - GuruFocus
Spyre Therapeutics stock hits 52-week high at 42.93 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics Stocks Surge Amid Cash Flow and Research Developments - timothysykes.com
How buybacks impact Spyre Therapeutics Inc. stock valueInflation Watch & Weekly Watchlist for Hot Stocks - mfd.ru
Spyre Therapeutics Surprises with Strong Q4 Despite Losses - StocksToTrade
Wells Fargo Raises Price Target for Spyre Therapeutics (SYRE) to $50 | SYRE Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price - MarketBeat
Spyre Therapeutics Stock Jumps on Pipeline Momentum - TipRanks
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3%Time to Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Receives Buy Rating from BTIG Research - MarketBeat
Spyre Therapeutics (SYRE) Stock Soars Over 11% - GuruFocus
Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight - GuruFocus
Spyre Therapeutics files for mixed shelf of up to $500 million - marketscreener.com
Spyre Therapeutics Files For Mixed Shelf Of Up To $500 Million - TradingView
Spyre (SYRE) Reports Decrease in R&D Expenses and Strong Cash Po - GuruFocus
Spyre Therapeutics Q4 Loss Narrows, Cash Runway Expected Into Q2 2028 - marketscreener.com
Spyre Therapeutics (SYRE) Initiates Mixed Securities Shelf Filin - GuruFocus
Spyre Therapeutics: Q4 Earnings Snapshot - kens5.com
Earnings Flash (SYRE) Spyre Therapeutics Posts Q4 Loss $-0.70, vs. FactSet Est of Loss of $-0.71 - marketscreener.com
Spyre Therapeutics (NASDAQ:SYRE) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):